Form 4: Arcellx Director Kavita Patel Executes Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Director Kavita Patel exercised stock options and sold shares of Arcellx, Inc. under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On February 4, 2025, Kavita Patel, a director of Arcellx, Inc., exercised stock options to acquire 1,500 shares of common stock at a price of $6.66 per share.
- On the same day, Patel sold 1,500 shares of Arcellx common stock at a price of $64.57 per share.
- The sale was conducted under a pre-arranged Rule 10b5-1 trading plan established on March 28, 2024.
- Following these transactions, Patel directly owns 0 shares.
- Patel also holds 36,077 derivative securities in the form of stock options.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing plan. There is no indication of positive or negative sentiment towards the company's prospects.
Industry Context
Sales by insiders are common and often pre-planned, especially in the biotech industry where stock options form a significant part of compensation. The use of a 10b5-1 plan suggests the insider is selling shares in a structured way to avoid accusations of insider trading.
Comparison to Industry Standards
- Insider trading activity is common across publicly listed companies, especially in the biotech sector.
- Companies like Amgen, Gilead, and Biogen also see regular Form 4 filings from their executives and directors.
- The use of 10b5-1 plans is a standard practice to ensure compliance with insider trading regulations, similar to what is seen at companies like Regeneron and Vertex Pharmaceuticals.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the sale of shares by a director.
- However, the pre-planned nature of the sale mitigates concerns about insider information influencing the decision.
Key Dates
| Date | Description |
|---|---|
| December 1, 2021 | Vesting Commencement Date for the 2017 Equity Incentive Plan |
| March 28, 2024 | Date of adoption of Rule 10b5-1 trading plan |
| February 4, 2025 | Date of option exercise and share sale |
| December 7, 2031 | Expiration date of the stock options |
Keywords
Arcellx, ACLX, Form 4, Kavita Patel, Stock Options, Rule 10b5-1, Director, Share Sale, Equity Incentive Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.